




RealRate

PHARMACEUTICAL 2021

BridgeBio Pharma Inc.
Rank 291 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of BridgeBio Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BridgeBio Pharma Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 34% points. The greatest weakness of BridgeBio Pharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -280%, being 75% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	642,824
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	95,648
Liabilities, Non-Current	116,618
Other Assets	40,439
Other Compr. Net Income	56,702
Other Expenses	0
Other Liabilities	383,436
Other Net Income	-31,006
Property and Equipment	20,325
Research and Development	337,047
Revenues	8,249
Selling, General and Administrative Expense	145,684

Output Variable	Value in 1000 USD
Assets	703,588
Liabilities	595,702
Expenses	482,731
Stockholders Equity	107,886
Net Income	-505,488
Comprehensive Net Income	-477,137
Economic Capital Ratio	-280%